This event took place online on February 9. Until our next TPD Webinar, you can register your interest here, or check out more TPD events and content brought to you by Hanson Wade:

TPD banner (3)

Welcome to the TPD: Emerging Disease Applications Beyond Oncology Digital Event!

Targeted protein degradation (TPD) is emerging to be a promising technology for targeting disease-causing proteins. Through the mechanism of hijacking either the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway the protein of interest is degraded, raising hope for the development of treatments targeting previously ''undruggable'' proteins involved in oncology, neurodegeneration, inflammatory and autoimmune disease. TPD has been attracting a lot of attention for cancer treatment with a handful of products making it into clinical trials, however, not much has been available about the progress of TPD besides oncology due to most products currently being found in discovery and pre-clinical stages. 

This digital event has been designed to reveal the emerging applications of TPD outside the field of oncology by hosting speakers working in the fields of neuroscience, inflammatory and autoimmune disease. Join expert speakers to discuss everything about the emerging discoveries in the field, targeting of the protein of interest, degrader selection, challenges in discovery and development as well as ways to overcome those and make it to the clinical stages.

Expert Speakers

Beth Hoffman

CEO

Origami Therapeutics

Hyunsun Jo

CEO

Pin Therapeutics

Jared Gollob

Chief Medical Officer

Kymera Therapeutics

Kumar Suresh

Senior Director & Head of Drug Discovery

Progenra

Why Attend:

Join to hear insights from experts holding leading positions in biopharma organizations working on TPD. Discover the latest advances in drug discovery and development in areas beyond oncology and get a sense of where the field is heading in the coming years.

Expert speakers will discuss current research in the fields of neurology, inflammatory and autoimmune disease including points concerning degrader type selection, ways to target proteins of interest, the challenges they are facing in proving efficacy and how to overcome them. You will also have the opportunity to ask questions and get high-quality comprehensive answers from speakers.